- FDA approves Omylco® (omalizumab), first biosimilar of Xolair®.
- After Q1, FDA and EMA on track for a record number of biosimilar authorizations in 2025.
Biosimilars, once a niche segment in the pharmaceutical industry, are now making a significant impact on global healthcare. These products are highly similar to an already-approved reference product, offering a more